Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
RORγt(+) cells selectively express redundant cation channels linked to the Golgi apparatus.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Multiple sclerosis causing a partial sixth nerve palsy.
Disease-modifying drugs for multiple sclerosis and JC virus expression.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis.
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells.
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
The unwavering commitment of regulatory T cells in the suppression of autoimmune encephalomyelitis: Another aspect of immune privilege in the CNS.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Genzyme to Resubmit LemtradaTM Application for FDA Review
Age-dependent effects on the treatment response of natalizumab in MS patients.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

Pages